An observational study in Prostate Cancer, Genetic Predisposition to Disease and BRCA Mutation, sponsored by Royal Marsden NHS Foundation Trust. Enrolling by invitation at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-27.
Sponsored by Royal Marsden NHS Foundation Trust · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust — 8 open to participants now, 10 under way, 1 of them phase 3. Prostatic Neoplasms · Royal Marsden NHS Foundation Trust.
Among the 21 studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust, this one is the only one that started in 2024, is one of 7 observational ones, and was the 16th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →8 of the 21 studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust are open now, in 2 countries. Recruiting first, the newest first:
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Ages 18–100 · Men only · Healthy volunteers
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Ages 18+ · Men only
Royal Marsden NHS Foundation Trust · Sites in Canada, United Kingdom
Ages 18+ · Men only
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Men only
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Ages 18+ · Men only · Healthy volunteers
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 3
First in 2000; this study’s year is marked. 1 started in 2024.
This study's planned enrollment of 20 is below the median of 200 across 1,312 observational studies indexed under Prostatic Neoplasms.
Median enrollment 81 across the 14 interventional studies, 100 across the 7 observational. Of the 2 that completed or were terminated, 1 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Royal Marsden NHS Foundation Trust is the lead sponsor of 275 studies on the registry; 54 are open to participants now.
4 of the studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06638541Royal Marsden NHS Foundation TrustDose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions | 2027-01-01 |
| NCT06019676Royal Marsden NHS Foundation TrustImpact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients | 2027-04-01 |
| NCT07870707Royal Marsden NHS Foundation TrustProstate Cancer in UK Prisons: A Retrospective Data Analysis | 2027-08-03 |
| NCT07741929Royal Marsden NHS Foundation TrustPatient and Provider Perspectives on Genetic Risk Profiling | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 21 studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prostate cancer affects 1-in-8 people assigned male at birth in the UK and kills almost 12,000 annually. Half the cases occur due to genetic factors. These include rare highly-penetrant mutations such as BRCA2 as well as a combination of common genetic variants. A 'polygenic risk score' can be used to identify people who may develop more aggressive forms of the disease. Prophylactic, or 'risk-reducing' mastectomy and oophorectomy has been shown to prevent mortality and be acceptable for healthy women with known genetic risks. There is no such evidence as yet of the benefits of similar surgery for people at a higher genetic risk of developing prostate cancer. However, this question is often posed in clinic by people who carry pathogenic variants in BRCA2. In the future we propose to develop a feasibility study offering prophylactic prostatectomy to people based on their high genetic risk.
Prior to this, we wish to undertake this pilot qualitative study to better understand patients' perspectives on the acceptability of the procedure. Prostatectomy carries risks, with potential impact on erectile function and urinary continence. In this year-long project we will conduct up to 20 semi-structured interviews with patients and public to explore acceptability and to identify informational and support needs envisaged by men contemplating prophylactic prostatectomy. We will invite people aged over 18 to take part. We will include a wide range of perspectives including those at higher genetic risk or a strong family history of prostate cancer, as well as those with unknown or normal genetic risk factors. We will include people from different socio-economic backgrounds and those of black ethnicity who carry a higher risk. They will be recruited from existing prostate cancer screening studies and from community organisations with expertise in working with under-served communities.
Prostate cancer (PrCa) is the most common cancer in people assigned male at birth in the UK, with over 50,000 new cases diagnosed and 12,000 lives lost to prostate cancer in the UK each year (Cancer Research UK, 2023). This is of particular concern for individuals of Black African and Black African Caribbean ancestry who carry a 1 in 4 risk of developing prostate cancer (compared with 1 in 6 individuals overall); for people with a family history of the disease and for people who have a genetic predisposition to prostate cancer (for example those who carry a pathogenic variant in a high-risk gene such as Breast Cancer 2(BRCA2) (Cancer Research UK, 2023; Page et al, 2019). As cancers tend to arise in the peripheries of the prostate gland, there may be few or no symptoms even from locally advanced disease until very late on. Even with symptoms, they can easily be conflated with benign disease or ignored as a typical feature of the ageing process (Gnanapragasam et al, 2022). Early diagnosis and treatment are potentially lifesaving for a range of conditions with late presentation a major cause of death from cancer. However early diagnosis is particularly challenging in cases where there is aggressive disease, which can manifest suddenly and spread rapidly beyond the prostate (Castro et al, 2013; 2015). There is also currently no screening programme for the early detection of prostate cancer as there are well documented concerns about the use of Prostate Specific Antigen (PSA) testing when applied to the general population (Cancer Research UK, 2023).
The aetiology of the disease remains very poorly understood. The substantial worldwide variation in incidence rates suggests that lifestyle risk factors are important. To date, however, no definite lifestyle risk factors have been identified. Aside from demographic factors, risk factors for prostate cancer include genetic factors arising from rare highly-penetrant mutations, and/or from common variants conferring more moderate risks. A number of genome wide associations studies have shown that a combination of common variants can also contribute to substantial risks. Furthermore, these also interact with rarer variants such as BRCA2. The top 1% of the risk distribution from common variants confers 5-11 times the relative risk of developing prostate cancer. These interact with the risks from BRCA2 mutations to increase the lifetime risk from 18% to greater than 60%. Prostate cancer in BRCA2 carriers occurs at a young age and may be more aggressive, and the optimal management is unknown (Nyberg et al, 2020). The impact of BRCA2 on people from African backgrounds is not known, however this group may be at even higher risk of prostate cancer.
The IMPACT study has investigated targeted prostate screening in BRCA2 carriers, showing a clear benefit of PSA-based screening in the early detection of clinically important prostate cancers (Page et al, 2019). The IMPACT team are working with the National Screening Committee to review their current PSA screening recommendations. However, this screening has only looked at risk stratification based on BRCA2 mutation status alone and has not investigated the impact of screening on people with BRCA2 incorporating a calculation of their common genetic variants, or 'polygenic risk score'.
Prophylactic, or 'risk-reducing' mastectomy is a well-established treatment for healthy women with a family history of breast cancer, a personal history of breast cancer together with a family history, or people with a known BRCA1/2 mutation to reduce their risk of developing breast cancer in the future (Bertozzi et al, 2023). Prophylactic bilateral salpingo-oophrectomy is offered to reduce their risk of breast and gynaecological cancers (Giannakeas \& Narod, 2018). There is a clear mortality benefit from undergoing prophylactic oophorectomy, and evidence to support that prophylactic mastectomy reduces mortality in younger people undergoing this procedure. High levels of satisfaction and quality of life following these procedures is also reported (Grandi et al, 2023; Razdan et al, 2016).
There is no such evidence as yet of the benefits of performing similar surgery for people at a higher genetic risk of developing prostate cancer, without evidence of the disease. However, this is a question often posed in clinic by people who carry pathogenic variants in BRCA2 who have at least a 25-60% chance of developing prostate cancer in their lifetime. We propose to develop a trial to recruit people to a feasibility study offering prophylactic prostatectomy based on their high genetic risk (combined high polygenic risk score and BRCA2 carrier status). Prior to this trial we wish to undertake this pilot qualitative study to better understand patients' perspectives on the acceptability and feasibility of the study. Prostatectomy is not without its own risks and the impact on quality of life namely, its effects on erectile dysfunction and urinary incontinence and consequent psychological impact of living with these side-effects. Appropriate counselling of people prior to their recruitment for such a study is key, and we feel that interviews seeking the views and perspectives of patients and the public (PPIE) would be imperative in order to inform the design of a future study with the necessary input from those affected.
There is no evidence as yet of the benefits of performing prophylactic prostatectomy for people at a higher genetic risk of developing prostate cancer, without evidence of the disease. People who carry a mutation in BRCA2 often ask why a prophylactic prostatectomy isn't offered when they may benefit from this procedure, and the research team propose to develop a feasibility study in the future. Research conducted with people undergoing prophylactic mastectomy and bilateral salpingo oophorectomy suggests that there are many nuanced personal factors to consider when providing information and advice about such an intervention (McGarrigle et al, 2021). These factors reflect the need for balance between reduced cancer worry and post-surgical side effects and potential emotional and inter-personal impact.
Before designing a feasibility study, it is therefore crucial to understand the likely factors that would influence people's decision-making and the potential psychosocial impact. This study will explore people's understandings, views and opinions on prophylactic prostatectomy in order to identify informational and support needs when planning future research.
We will invite people aged 18 and over to take part in this research, including those at higher genetic risk based either on the result of a genetic test (including people who have a pathogenic variant in etihter the BRCA1 or BRCA2), people with a strong family history of prostate cancer, or of black ethnicity. We will include people who have not had any previous prostate surgery, and people who have had a prostatectomy as part of their cancer treatment.
We aim to recruit from different socio-economic backgrounds and those of black ethnicity who are at higher-risk of developing prostate cancer. They will be recruited from RMH prostate cancer screening studies and from community organisations with links and expertise in working with under-served communities.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Unaffected people (ie no previous prostate surgery) assessed to be living at higher risk of prostate cancer based on either:
Exclusion criteria:
Research Interviews
What would be the uptake of prophylactic prostatectomy?
To explore people's understandings, views and opinions on hypothetical prophylactic prostatectomy for those at high genetic risk of developing prostate cancer.
Time frame: Opinions collected and analysed over 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Jun 2025, 12 months after the start.
Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 12 months is below that.
Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Royal Marsden NHS Foundation Trust →